AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disordersDAWSON, Mark A; CURRY, Jayne E; THOMPSON, Neil T et al.British journal of haematology. 2010, Vol 150, Num 1, pp 46-57, issn 0007-1048, 12 p.Article

Molecular Pathways: Molecular Basis for Sensitivity and Resistance to JAK Kinase InhibitorsMEYER, Sara C; LEVINE, Ross L.Clinical cancer research (Print). 2014, Vol 20, Num 8, pp 2051-2059, issn 1078-0432, 9 p.Article

JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitationsPARDANANI, A; VANNUCCHI, A. M; PASSAMONTI, F et al.Leukemia. 2011, Vol 25, Num 2, pp 218-225, issn 0887-6924, 8 p.Article

PLA2R1 Mediates Tumor Suppression by Activating JAK2VINDRIEUX, David; AUGERT, Arnaud; DE LAUNOIT, Yvan et al.Cancer research (Chicago, Ill.). 2013, Vol 73, Num 20, pp 6334-6345, issn 0008-5472, 12 p.Article

Targeting myeloproliferative neoplasms with JAK inhibitorsPARDANANI, Animesh; TEFFERI, Ayalew.Current opinion in hematology. 2011, Vol 18, Num 2, pp 105-110, issn 1065-6251, 6 p.Article

JAK2 inhibitors: What's the true therapeutic potential?SANTOS, Fabio P. S; VERSTOVSEK, Srdan.Blood reviews. 2011, Vol 25, Num 2, pp 53-63, issn 0268-960X, 11 p.Article

JAK2 V617F and ringed sideroblasts : not necessarily RARS-TSTEENSMA, David P; TEFFERI, Ayalew.Blood. 2008, Vol 111, Num 3, pp 1748-1748, issn 0006-4971, 1 p.Article

Janus kinase inhibitors for the treatment of myeloproliferative neoplasmsROSENTHAL, Allison; MESA, Ruben A.Expert opinion on pharmacotherapy. 2014, Vol 15, Num 9, pp 1265-1276, issn 1465-6566, 12 p.Article

Identification of JAK2^V617F in patients with polycythemia is highly correlated with conventional criteria for diagnosis of polycythemia veraGANLY, Peter; HANRAHAN, Vickie; BAKER, Bart et al.American journal of hematology. 2007, Vol 82, Num 1, pp 80-82, issn 0361-8609, 3 p.Article

Involvement of ERK and JNK pathways in IFN-γ-induced B7-DC expression on tumor cellsJUNFANG DENG; YIGANG QIAN; LEI GENG et al.Journal of cancer research and clinical oncology. 2011, Vol 137, Num 2, pp 243-250, issn 0171-5216, 8 p.Article

CLEC-2 and Syk in the megakaryocytic/platelet lineage are essential for developmentFINNEY, Brenda A; SCHWEIGHOFFER, Edina; SHEARDOWN, Steve et al.Blood. 2012, Vol 119, Num 7, pp 1747-1756, issn 0006-4971, 10 p.Article

Expression level and differential JAK2-V617F-binding of the adaptor protein Lnk regulates JAK2-mediated signals in myeloproliferative neoplasmsBARAN-MARSZAK, Fanny; MAGDOUD, Hajer; GIRAUDIER, Stéphane et al.Blood. 2010, Vol 116, Num 26, pp 5961-5971, issn 0006-4971, 11 p.Article

Liar, a novel Lyn-binding nuclear/cytoplasmic shuttling protein that influences erythropoietin-induced differentiationSAMUELS, Amy L; KLINKEN, S. Peter; INGLEY, Evan et al.Blood. 2009, Vol 113, Num 16, pp 3845-3856, issn 0006-4971, 12 p.Article

Src family tyrosine kinase Lyn mediates VWF/GPIb-IX-induced platelet activation via the cGMP signaling pathwayHONG YIN; JUNLING LIU; ZHENYU LI et al.Blood. 2008, Vol 112, Num 4, pp 1139-1146, issn 0006-4971, 8 p.Article

The JAK kinase inhibitor CP-690,550 supresses the growth of human polycythemia vera cells carrying the JAK2^V617F mutationMANSHOURI, Taghi; QUINTKS-CARDAMA, Alfonso; NUSSENZVEIG, Roberto H et al.Cancer science. 2008, Vol 99, Num 6, pp 1265-1273, issn 1347-9032, 9 p.Article

«JAK» a dit : c'est un syndrome myéloprolifératif = JAK2 V617F mutation and the myeloproliferative disordersVAINCHENKER, William; CASADEVALL, Nicole.Hématologie (Montrouge). 2006, Vol 12, Num 1, pp 3-7, issn 1264-7527, 5 p.Article

Inhibitory effect of tyrphostin 47 on Shiga toxin-induced cell deathIKEDA, Masahiro; GUNJI, Yasuhiro; SONODA, Hiroko et al.European journal of pharmacology. 2006, Vol 546, Num 1-3, pp 36-39, issn 0014-2999, 4 p.Article

Physiopathologie des syndromes myéloprolifératifs non LMC : Syndrome myéloprolifératif hors LMC = Pathogenesis of BCR-ABL négative myeloproliferative disordersJAMES, C.Correspondances en onco-hématologie. 2008, Vol 3, Num 3, pp 122-126, issn 1954-4820, 5 p.Article

Metabolism, Excretion, and Pharmacokinetics of [¹⁴C]INCB018424, a Selective Janus Tyrosine Kinase 1/2 Inhibitor, in HumansSHILLING, Adam D; NEDZA, Frank M; SHEPARD, Stacey et al.Drug metabolism and disposition. 2010, Vol 38, Num 11, pp 2023-2031, issn 0090-9556, 9 p.Article

Aberrant DNA methylation of the Src kinase Hck, but not of Lyn, in Philadelphia chromosome negative acute lymphocytic leukemiaHOSHINO, K; QUINTAS-CARDAMA, A; YANG, H et al.Leukemia. 2007, Vol 21, Num 5, pp 906-911, issn 0887-6924, 6 p.Article

Use of synthetic amino acid polymers for assay of protein-tyrosine and protein-serine kinasesRACKER, E.Methods in enzymology. 1991, Vol 200, pp 107-111, issn 0076-6879Article

CYT387, a selective JAK1 /JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patientsPARDANANI, A; LASHO, T; SMITH, G et al.Leukemia. 2009, Vol 23, Num 8, pp 1441-1445, issn 0887-6924, 5 p.Article

Is the JAK2^V617F mutation detectable in healthy volunteers?MARTINAUD, Christophe; BRISOU, Patrick; MOZZICONACCI, Marie-Joelle et al.American journal of hematology. 2010, Vol 85, Num 4, pp 287-288, issn 0361-8609, 2 p.Article

JAK inhibitors in myeloproliferative neoplasms: Rationale, current data and perspectiveTEFFERI, A; PARDANANI, A.Blood reviews. 2011, Vol 25, Num 5, pp 229-237, issn 0268-960X, 9 p.Article

Janus Kinase MutationsLEVINE, Ross L.Seminars in oncology. 2009, Vol 36, Num 2, issn 0093-7754, S6-S11, SUP1Article